[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512829":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":117,"collaborators":19,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":19,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":19,"enrollmentInfo":128,"targetDuration":19,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"D3 Bio (Wuxi) Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"D3L-001","EXPERIMENTAL","Part 1 Dose Escalation in subjects with HER2-positive advanced solid tumors\n\n* Cohort 1 (starting dose)\n* Cohort 2\n* Cohort 3\n* Cohort 4\n* Cohort 5\n* Cohort 6\n* Cohort 7\n* Cohort 8\n\nPart 2 Dose Expansion\n\n* Cohort A for subjects with HER2-positive advanced breast cancer\n* Cohort B for subjects with HER2-positive advanced gastric cancer\u002Fgastroesophageal junction cancer",[13],"Biological: D3L-001",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Intravenous administration",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Medical Director","CONTACT","+86 21 61635900","D3bio_CT@d3bio.com",[27,41,50,58,68,79,88,99,108],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"D3 Bio Investigative Site","RECRUITING","Stanford","California","94305","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-122.16608,37.42411,{"lat":39,"lon":38},{"facility":28,"status":29,"city":42,"state":43,"zip":44,"country":33,"countryCode":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":19},"Boston","Massachusetts","02215",{"type":36,"coordinates":46},[47,48],-71.05977,42.35843,{"lat":48,"lon":47},{"facility":28,"status":29,"city":51,"state":51,"zip":52,"country":33,"countryCode":34,"cosmosGeoPoint":53,"geoPoint":57,"contacts":19},"New York","10065",{"type":36,"coordinates":54},[55,56],-74.00597,40.71427,{"lat":56,"lon":55},{"facility":28,"status":59,"city":60,"state":61,"zip":62,"country":33,"countryCode":34,"cosmosGeoPoint":63,"geoPoint":67,"contacts":19},"TERMINATED","San Antonio","Texas","78229",{"type":36,"coordinates":64},[65,66],-98.49363,29.42412,{"lat":66,"lon":65},{"facility":28,"status":29,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":19},"Sydney","New South Wales","2109","Australia","AU",{"type":36,"coordinates":75},[76,77],151.20732,-33.86785,{"lat":77,"lon":76},{"facility":28,"status":29,"city":80,"state":81,"zip":82,"country":72,"countryCode":73,"cosmosGeoPoint":83,"geoPoint":87,"contacts":19},"Malvern","Victoria","3144",{"type":36,"coordinates":84},[85,86],145.02811,-37.86259,{"lat":86,"lon":85},{"facility":28,"status":29,"city":89,"state":90,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":19},"Harbin","Heilongjiang","150088","China","CN",{"type":36,"coordinates":95},[96,97],126.65,45.75,{"lat":97,"lon":96},{"facility":28,"status":29,"city":100,"state":101,"zip":102,"country":92,"countryCode":93,"cosmosGeoPoint":103,"geoPoint":107,"contacts":19},"Shanghai","Shanghai Municipality","200025",{"type":36,"coordinates":104},[105,106],121.45806,31.22222,{"lat":106,"lon":105},{"facility":28,"status":29,"city":109,"state":110,"zip":111,"country":92,"countryCode":93,"cosmosGeoPoint":112,"geoPoint":116,"contacts":19},"Hangzhou","Zhejiang","310022",{"type":36,"coordinates":113},[114,115],120.16142,30.29365,{"lat":115,"lon":114},{"type":118,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100512829","phase-1-a-study-of-d3l-001-as-monotherapy-in-subjects-with-her2-positive-advanced-solid-tumors-100512829",false,"NCT05957536","A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors","A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.","Inclusion Criteria:\n\n* Subject must have documented HER2 positivity (determined by immunohistochemistry \\[IHC\\], in situ hybridization \\[ISH\\], Next Generation Sequencing \\[NGS\\] or other analysis techniques as appropriate).\n* Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Subject must have left ventricular ejection fraction (LVEF) ≥50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within the screening period.\n* Subject must have adequate organ and marrow function within the screening period.\n\nExclusion Criteria:\n\n* Subject has any prior treatment with anti-CD47 or SIRPα agent.\n* Subject has any prior treatment without adequate washout periods as defined in the protocol.\n* Subject has immunosuppressive medication that is not completed 14 days before the first dose of study medication.\n* Subject has uncontrolled intercurrent illness that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n* Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).\n* Judgment by the Investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions, and requirements.","ALL","18 Years",{"count":129,"type":130},128,"ESTIMATED","INTERVENTIONAL",[133],"PHASE1","This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.",[136],"HER-2 Positive Advanced Solid Tumors",[138,139],"HER-2 Positive","Advanced Solid Tumors","2026-03-11",{"date":142,"type":143},"2026-03-13","ACTUAL",{"date":145,"type":143},"2023-09-19",{"date":147,"type":130},"2028-12-19",{"name":5,"class":6},9]